Real-world dostarlimab use in advanced/ recurrent endometrial cancer in France

Introduction > In October 2020, the French Health Authority granted early access outside of the clinical trial setting for dostarlimab, a programmed death-1 inhibitor. Dostarlimab was approved by the European Medicines Agency (in April 2021) as monotherapy for patients with post-platinum mismatch repair deficient/microsatellite instability-high advanced/recurrent endometrial cancer, based on the results of the GARNET trial (NCT02715284).Methods > This was a real-world descriptive analysis of patients granted cohort temporary authorization of use to receive dostarlimab between November 2020 and June 2021. Physicians could complete follow-up forms at each treatment cycle to provide clinical information, safety, and efficacy data. Safety and disease progression data were also captured through pharmacovigilance reports.Results > Of 95 temporary authorization of use requests made by 80 oncologists in 59 French hospitals, 87 patients were eligible, and 80 received >= 1 dose of dostarlimab. Based on treatment response assessments received (n = 43), the mean (standard deviation) time from treatment initiation to response evaluation was 11 (6) weeks. The disease control rate (complete plus partial responses plus stable disease rates) was 56% (n = 24/43), and the overall response rate was 35% (n = 15/43); both consistent with those reported in the GARNET trial. No new safety signals were reported.Discussion > The enrolment of 80 patients in an 8-month period highlights the need for access to novel treatment regimens in France for these patients post-platinum. Prospective randomized studies are ongoing to assess the efficacy and safety of dostarlimab and other checkpoint inhibitors as first-line treatment in patients with endometrial cancer.

Automated summary

This study conducted a descriptive analysis of patients granted temporary authorization to use dostarlimab, finding that the treatment response rate and disease control rate were consistent with clinical trial results. The study highlights the need for novel treatment options for patients in France who have undergone platinum-based therapy.